Ipca Laboratories Q4 FY26: A Margin Story Meets Raw-Material Headwinds

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

Prices referenced are not live.

1. At a Glance

Ipca’s Q4 and FY26 results show a company reshaped by mix—higher domestic, stronger ROW formulations, and API margin expansion—yet arrival at a fork. Net profit grew 80.9% YoY to ₹332 Cr in Q4, but consolidated revenue crawled at just 6% to ₹2,388 Cr, dragged by the Unichem acquisition’s structural margin compression (EBITDA fell to 8% from 12%, taking the blended story down with it).

Standalone Ipca meanwhile flexed: revenue ₹2,033 Cr (Q4 FY24) → ₹2,388 Cr (Q4 FY26) at stronger margins (25% OPM). Management guided FY27 consolidated growth at 12–13% and margin of 22–22.3%—but raw material inflation (10–12% expected, with solvents 40–50% above January pricing) and freight escalation (~25% in Q4, driven by geopolitics) now shadow that outlook.

The Unichem recovery is positioned as FY27’s lever: Ireland overheads (€4–5m) gone, US share coming back, margins back to 12–13%. If it sticks, the math works. If cost headwinds persist unchecked, margin guidance becomes a tug-of-war.

Does a margin recovery powered by operational fixes offset the arithmetic of double-digit cost inflation? The number won’t answer until Q1 FY27 lands.

2. Introduction

Ipca Laboratories entered FY25 with acquisition hunger—Unichem Laboratories in August 2023, then the Ireland footprint in May 2025 (100% equity). The intent: a real US generics entry (Unichem’s marketed products: ~8 SKUs; FY27 pipeline: 6–8 more) and operational scale in ROW geographies. FY26 had a full-year slug of Unichem revenue but only partial margin recovery. Meanwhile, standalone Ipca proved resilient—domestic formulations climbed 10%, exports took 9%, APIs grew 10%—all amid a competitive Indian pharma backdrop and regulatory vigilance (three facilities cleared of USFDA import alert in FY24; Tarapur facility inspected Dec 2025, Form 483 issued, status VAI—minimally acceptable CGMP).

The company also commissioned a ₹182-Cr greenfield API facility at Hingani, Wardha in February 2026, and a Pisgah Labs (US formulations facility) is expected to open in Q4 FY27. Capex intensity spiked in FY25 (₹7,756 Cr) and is expected to moderate in FY26 (“almost 60% of expansion capex spent in FY25”). Field force stands at ~13,250 (per concall). On governance, credit ratings remain IND AA+/Stable (India Ratings, July 2025); pledges are zero.

3. Business Model: WTF Do They Even Do?

Ipca is a vertically integrated pharmaceutical factory. The company manufactures over 350 formulations (tablets, capsules, injectables, creams, etc.) across nearly every therapy—pain, cardiovascular, anti-diabetics, dermatology, antibacterials, anti-malaria—and over 80 active pharmaceutical ingredients (APIs) for export. Fully integrated means: Ipca makes the powder, then the pill, then ships it, all under one roof (or across owned facilities). That’s rare in generics; most competitors farm out.

FY26 Revenue Mix (₹9,646 Cr):

• Domestic formulations: ₹3,817 Cr (39%)
• Export formulations (Ipca): ₹2,083 Cr (22%)
• APIs & intermediates: ₹1,396 Cr (14%)
• Subsidiary sales (mainly Unichem): ₹2,350 Cr (24%)

The Unichem drag: Unichem (acquired Aug 2023, now 100% owned) contributed ~₹2,350 Cr in FY26 but at only 8% EBITDA margin vs its prior 12%. The company had a tough US generics year (lost share in “high-volume businesses,” now recovering) and carries elevated Ireland overheads that closure will remove. Without Unichem, the standalone Ipca mix looks sharper: domestic 39% (higher-margin branded), promotional/branded exports 26% (14% growth YoY to ₹664 Cr), generic exports 29% (17% growth to ₹1,149 Cr), API 14%.

Strengths of the model: Backward integration (API-to-formulation) hedges supply chain shocks and price erosion in regulated (e.g., India price-control) markets. Export concentration (79% of API/Intermediates biz) de-risks domestic-only exposure. Pain management is flagship—Zerodol brand ranks 3rd nationally (₹13 Bn revenue, 8% market share, per Pharmatrac MAT Mar’26). Six brands in top 300 nationally.

Friction points: Institutional sales (funding-constrained customers) fell ₹85 Cr YoY to ₹270 Cr in FY26. Regulatory vigilance is real—Tarapur inspected Dec 2025, US FDA clearances for three import-alert facilities achieved but ongoing inspections required. Gross margins (not reported standalone in this set) hinge on raw-material cost and product mix; a 10–12% input inflation is non-trivial at current scale.

4. Financials Overview

Figures are consolidated, in ₹ crore.

Quarterly narrative (Q4 FY26 vs Q4 FY25): Revenue was flat-ish (6% growth), masked a positive: standalone Ipca grew, Unichem remained pressured. PAT jumped 38%, but was aided by a lower tax rate (24% vs 28%) and a one-time reversal or favorable item (concall noted Q4 FY26 “other expenses” spiked to ₹2,685 Cr—largely non-recurring: ₹19-24 Cr for tech transfers to US manufacturers, plus prior-year adjustments). Operating profit (EBITDA) rose 14.8% to ₹490 Cr, and OPM ticked up to 20.5%, reflecting standalone Ipca’s margin lift (+252 bps YoY to 25.2%) offset partially by Unichem’s 8% OPM.

Full-year narrative (FY26 vs FY25): Revenue growth of 8% mirrors the macroeconomic and competitive backdrop—India market grew 8.4%, Ipca outpaced slightly (domestic formulations at 10%, exports 9%, API 10%). EBITDA margin expanded 116 bps to 20.5%, a beat vs management’s 20% guidance, driven by “product mix changes”: higher domestic, higher ROW, higher cardiac (a margin-richer therapy), API margin accretion. Unichem, however, dragged: absent its 8% OPM, consolidated would have been 21–22%. Net profit surged 40% YoY, lifted by EBITDA growth, lower interest (down 37% YoY to ₹76 Cr—debt refinancing and paydown), and a favorable tax rate (24% vs 30%).

Standalone Ipca (per FY25 rating report, updated concall framing): Revenue grew 8.3% to ₹6,678 Cr in FY26 (implied from rating report FY25 number ₹6,180 Cr); EBITDA margin expanded to 22.8% in FY25 (319 bps YoY). Concall emphasized standalone EBITDA margin of 25.2% in FY26, a 252-bp jump, underscoring the clean operational leverage behind the consolidated number.

5. Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market currently prices Ipca at 34.2x trailing earnings, a slight discount to its own 5-year average (38.1x) and a modest premium to the peer median (31.7x). EV/EBITDA sits at 19.2x, elevated relative to historical norms for the pharma cohort. The company’s ROE (16%) trails its past 3-year average (13.1%), supported by stronger recent profitability and lower equity base (after Unichem’s dilution has since been consolidated). ROCE at 17.3% sits above both